The following stories appear in full on today's Vidyya Medical News Service Web site.
Glaxo Wellcome, of Research Triangle Park, NC, has informed the FDA that it will voluntarily withdraw Lotronex (alosetron hydrochloride) tablets from the market. Lotronex is a prescription medication approved to treat Irritable Bowel Syndrome(IBS) in women. The FDA is advising patients taking Lotronex to contact their healthcare providers to discuss treatment alternatives.
Lotronex has been associated with reports of serious side effects such as intestinal damage as a result of reduced blood flow to the intestine (ischemic colitis), severely obstructed or ruptured bowels (complications of severe constipation), and death. Get the information you and your patients need in today's issue.
Vidyya has kept a careful eye on the Ebola virus outbreak in Uganda. Now, as described in the November 30 issue of Nature, a team of researchers led by scientists from the National Institutes of Health (NIH) has developed a novel vaccine that prevents Ebola virus infection in monkeys. All four vaccinated monkeys were completely protected from a lethal dose of the virus.
A vaccine against fungal infections? This good news may soon be a reality and none too soon as the rate of new fungal infections in the US and worldwide skyrocket. Scientists have used recombinant DNA technology to create a live vaccine that protects against a fungal infection in mice. This new vaccine is safer than live vaccines made without recombinant technology and more effective than "killed" vaccines.
World AIDS Day began in 1988 as a day to focus global attention on the HIV/AIDS epidemic across countries, organizations, and governments. Each year World AIDS Day has a theme; this year's theme is: "Men Make A Difference." Tomorrow, Vidyya will contain fact sheets and new research information regarding AIDS. To help you prepare for tomorrow's planned AIDS media blitz, today's issue contains a excellent booklet from the WHO, CDC, Gay Men's Health Crisis and the World AIDS Day Advisory Committee.
Today's Vidyya articles are:
As always, we hope you enjoy the issue.